Odylia Therapeutics is a nonprofit organization working to bring treatment for rare eye diseases from the lab into phase I/II clinical trials using AAV and other genetic therapies. There are more than 250 genetic forms of Inherited Retinal Disease (IRD) that lead to blindness. Most are extremely rare, affecting only one in a million people worldwide. Today there is pre-clinical proof-of-concept for treatments for more than 30 of these diseases, with more being discovered every day. Because these diseases are so rare, there is little commercial interest, leaving us to find a way to move these potential therapies into clinical trials to prevent blindness.